生物医药行业CNS创新药系列报告（三）：多款DMT进入3期阶段，PD药物市场有望快速成长

Investment Rating - The report maintains a positive outlook on the biopharmaceutical industry, specifically for Parkinson's disease (PD) drugs, indicating a potential for rapid market growth due to multiple disease-modifying therapies (DMTs) entering phase 3 trials [2][4]. Core Insights - The report highlights the unmet clinical needs in the PD drug market, emphasizing the lack of evidence-based disease-modifying treatments and the reliance on symptomatic therapies [3][8]. - The global PD drug market is projected to grow steadily, with an estimated market size of USD 5.56 billion in 2024, reaching USD 6.63 billion by 2029, reflecting a compound annual growth rate (CAGR) of 3.58% [4][5]. - The increasing prevalence of PD, particularly among the aging population, is expected to drive demand for innovative therapies that address unmet clinical needs [4][19]. Summary by Sections Unmet Clinical Needs in PD - Current PD drugs primarily increase dopamine levels in the brain but do not modify disease progression [9][11]. - Long-term use of levodopa and other medications can lead to motor complications, complicating the management of symptoms [16][15]. Focus on Disease-Modifying Therapies (DMTs) - DMTs have become a focal point in PD drug development, with 63 ongoing clinical trials targeting disease modification [19][21]. - The most researched DMT targets include alpha-synuclein, cell therapies, and GLP-1 receptor agonists [33][34]. Market Growth Potential - The number of PD patients in China is expected to rise significantly, from 1.99 million in 2005 to 5 million by 2030, potentially accounting for half of the global PD patient population [4][5]. - The report anticipates that the PD drug market will continue to expand as more innovative treatments are approved, particularly those that can modify disease progression [4][19]. Recommended Companies - The report recommends companies such as Green Leaf Pharmaceutical, which has received approval for a new drug, and Heng Rui Pharmaceutical, which has completed patient dosing for a dual-gene drug [4][5].